Baijin Life Science Holdings Limited Stocks

HK$ 0.53Last Updated 30.04.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

HK$ 53.29M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 0.53
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Affluent Partners Holdings Limited, an investment holding company, engages in the purchase, process, design, production, assembly, trade, and wholesale distribution of pearls and jewelry products. It operates in two segments, Sales of Pearls and Jewellery Products, and Strategic Investment and Financial Services. The company is also involved in the real estate financial assets investment business. It has operations in Hong Kong, the United Kingdom, the United States, Japan, Europe, and the People's Republic of China. The company was formerly known as Man Sang Jewellery Holdings Limited and changed its name to Affluent Partners Holdings Limited in February 2017. Affluent Partners Holdings Limited was incorporated in 2014 and is based in Central, Hong Kong.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks